1JHT
Crystal structure of HLA-A2*0201 in complex with a nonameric altered peptide ligand (ALGIGILTV) from the MART-1/Melan-A.
1JHT の概要
エントリーDOI | 10.2210/pdb1jht/pdb |
関連するPDBエントリー | 1JF1 |
分子名称 | HLA CLASS I HISTOCOMPATIBILITY ANTIGEN, A-2 ALPHA CHAIN, beta-2-microglobulin, nonameric peptide ligand from the MART-1/Melan-A, ... (4 entities in total) |
機能のキーワード | human, tumor immunity, melanoma antigen, mhc, vaccination, melanoma, class i, immune system |
由来する生物種 | Homo sapiens (human) 詳細 |
細胞内の位置 | Membrane; Single-pass type I membrane protein: P01892 Secreted: P61769 |
タンパク質・核酸の鎖数 | 3 |
化学式量合計 | 44589.62 |
構造登録者 | Sliz, P.,Michielin, O.,Karplus, M.,Romero, P.,Wiley, D. (登録日: 2001-06-28, 公開日: 2001-09-14, 最終更新日: 2024-10-30) |
主引用文献 | Sliz, P.,Michielin, O.,Cerottini, J.C.,Luescher, I.,Romero, P.,Karplus, M.,Wiley, D.C. Crystal structures of two closely related but antigenically distinct HLA-A2/melanocyte-melanoma tumor-antigen peptide complexes. J.Immunol., 167:3276-3284, 2001 Cited by PubMed Abstract: We have determined high-resolution crystal structures of the complexes of HLA-A2 molecules with two modified immunodominant peptides from the melanoma tumor-associated protein Melan-A/Melanoma Ag recognized by T cells-1. The two peptides, a decamer and nonamer with overlapping sequences (ELAGIGILTV and ALGIGILTV), are modified in the second residue to increase their affinity for HLA-A2. The modified decamer is more immunogenic than the natural peptide and a candidate for peptide-based melanoma immunotherapy. The crystal structures at 1.8 and 2.15 A resolution define the differences in binding modes of the modified peptides, including different clusters of water molecules that appear to stabilize the peptide-HLA interaction. The structures suggest both how the wild-type peptides would bind and how three categories of cytotoxic T lymphocytes with differing fine specificity might recognize the two peptides. PubMed: 11544315主引用文献が同じPDBエントリー |
実験手法 | X-RAY DIFFRACTION (2.15 Å) |
構造検証レポート
検証レポート(詳細版)をダウンロード